返回 Agenda
[V7-S1] The Trial Introduction of HTA in Japan - Latest Trends
Session Chair(s)
Shinzo Hiroi, PhD, MPH, RPh, PMP
Senior Director, Project Management, IDC ICO Real World Solutions
ICON Clinical Research GK, Japan
A Health Technology Assessment (HTA) trial was introduced in Japan in April 2016 and full-scale introduction of cost-effectiveness assessment based on HTA is scheduled in the future. We now must establish common awareness of “the value of pharmaceuticals and medical equipment and the assessment method” among relevant stakeholders. Highly transparent discussion is required from a more comprehensive perspective regarding the ideal cost-effectiveness assessment for balancing the advancement of highly innovative medical technology and the need to sustain currently strained health care financing in Japan. In this session, stakeholders from industry, government, and academia will freely discuss their viewpoint on the latest trends in cost-effectiveness assessment.
Speaker(s)
Trial Introduction of Cost-Effectiveness Evaluations in Japan
Kaoru Manabe, MD, PhD
Ministry of Health, Labour and Welfare (MHLW), Japan
Minister's Secretariat, Senior Deputy Director
From Academia's Perspective (Tentative)
Ataru Igarashi, PhD
The University of Tokyo, Japan
Associate Professor
From Consulting Firm's Perspective
Makoto Kobayashi, PhD
CRECON Medical Assessment Inc., Japan
Director and Chief Operating Officer
Trial Introduction of HTA from Pharmaceutical Industry's Perspective
Shuichi Yamaguchi
Chugai Pharmaceutical Co., Ltd., Japan
Group Manager, External Affairs Department